MS4A2 and allergic disease: For allergic diseases and asthma, FcεRIβ is an ideal target for SSO therapy, since it has a characteristic role in IgE-mediated mast cell activation that is inhibited by SSO-mediated alternative splicing of the MS4A2 gene.